Here's a cool piece of biotech news that's more about building a massive dataset than a flashy drug trial. Seer Inc. (SEER) said on Thursday that its Proteograph Product Suite—a fancy set of tools for mapping proteins—has been tapped as the go-to mass spectrometry workflow for a huge health study in Singapore. The plan is to profile the "plasma proteome" (that's all the proteins floating in blood) of 10,000 people participating in something called the PRECISE-SG100K study.
But Seer isn't going it alone. Researchers are going to take the dataset from Seer's platform and mash it up with the outputs from two tools made by Thermo Fisher Scientific Inc. (TMO): the Olink Reveal and Orbitrap Astral mass spectrometers. They're applying all these different technologies to the exact same set of blood samples. The idea is that by looking at the proteins through multiple, complementary lenses, they can get a much deeper, more validated understanding than any single method could provide on its own.
The Big Picture: A 100,000-Person Data Treasure Trove
So, what's this PRECISE-SG100K thing all about? It's a massive, long-term research program with the ambitious goal of enrolling around 100,000 residents of Singapore. It's a "multi-ancestry cohort," meaning it's designed to capture genetic diversity across Asian populations. The program isn't just collecting protein data; it's combining genomic (DNA), proteomic (protein), and clinical health data all in one place.
By throwing Seer's Proteograph platform into the mix alongside other tools for imaging and measuring physical traits, the study aims to build what scientists call a "comprehensive multi-omic dataset." Think of it as building the most detailed health profile possible for a large group of people. The end game? This kind of resource is a goldmine for precision health research, figuring out better ways to prevent diseases, and discovering new targets for drugs.
Adding deep, large-scale protein analysis is a big deal because proteins are the workhorses of the body. They're what your genes instruct your cells to make, and they're directly involved in health and disease. This data can act as a crucial "mechanistic layer" that helps explain how differences in your DNA (genetic variation) actually lead to differences in how your body functions (protein activity) and, ultimately, to different health outcomes. Researchers are betting this will be key for validating new disease biomarkers, spotting promising drug targets, and building better models to predict disease risk across entire populations.
How the Tech Fits Together
Seer's particular approach, especially when paired with Thermo's Astral mass spectrometer, has shown it can handle huge numbers of samples while still identifying and quantifying thousands of individual proteins with fine-grained detail. This mass spectrometry-based method is seen as a powerful complement to other protein-measuring platforms, like the affinity-based Olink Reveal system.
In large-scale studies, using both types of technology is becoming the preferred strategy. They can cross-validate each other's findings, and mass spectrometry can often detect a wider, deeper range of proteins, expanding on what affinity-based tools can see. It's a classic case of the whole being greater than the sum of its parts.
What's the Data Good For?
The potential applications are broad. Researchers expect the protein data from this Singapore cohort, as well as from other studies Seer is involved in (like one with Korea University), to fuel biomarker discovery across a range of tough diseases. We're talking about heart and metabolic conditions, neurological disorders, eye diseases, and more. Beyond just finding markers of disease, this deep protein data is also crucial for the early-stage research that identifies new targets for drugs to hit.
Perhaps just as importantly, this work focuses on an Asian population, which has historically been underrepresented in large biomedical datasets. The insights gained could lead to more accurate predictive models for disease risk and treatment response that actually work for these communities.
A Quick Look at Seer's Recent Business
Shifting gears to the financials for a moment: back in February, Seer reported its fourth-quarter results. The company posted a loss of 29 cents per share, which was actually better than the 32-cent loss analysts were expecting. Sales came in at $4.20 million, up 5% year-over-year, though that figure missed the consensus estimate of $4.6 million.
Looking ahead, the company's sales guidance for fiscal 2026 is in the range of $16 million to $18 million. The analyst consensus had been sitting higher, at around $22.1 million.
On the legal front, Seer scored a win recently. The Patent Trial and Appeal Board upheld key claims in Seer's patents covering its nanoparticle-based technology for enriching proteins from various sources like cells, tissues, and blood. This decision came in a challenge brought by subsidiaries of Bruker Corporation (BKR), a competitor in the life science tools space.
As for the stock, shares of Seer closed at $1.69 on Wednesday.
